Weil Company’s CollPlant Biotechnologies CLGN Stock Holding History

Weil Company’s Portfolio CLGN Stock Details CLGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-21,210	Closed	-$347K	–	129
2021 Q4	$347K	Sell	21,210 -3,348	-14%	-$59.7K	0.16%	102
2021 Q3	$415K	Sell	24,558 -5,910	-19%	-$106K	0.22%	86
2021 Q2	$646K	Sell	30,468 -4,500	-13%	-$71.9K	0.33%	75
2021 Q1	$470K	Buy	+34,968	New	+$527K	0.27%	82

Other funds holding CLGN

RAM

Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return

IMOV

Investment Management of Virginia Richmond, Virginia $526M AUM 3.23% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

BFEC

Benjamin F. Edwards & Company St. Louis, Missouri $5.69B AUM 15.37% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Weil Company's CLGN Position: Q1 2022 in Review

Weil Company sold out of CollPlant Biotechnologies (CLGN) in Q1 2022, closing a stake of 21,210 shares — an estimated $347K sold.

Weil Company first reported a position in CLGN in Q1 2021 and held it in 4 quarters. The position peaked at $646K in Q2 2021. 16 funds tracked by Wall St. Rank hold CLGN as of Q1 2022.

Weil Company reported no remaining CollPlant Biotechnologies position as of Q1 2022 after selling out during the quarter.
Weil Company sold 21,210 CollPlant Biotechnologies shares in Q1 2022, an estimated $347K.
Weil Company first reported a position in CollPlant Biotechnologies in Q1 2021 and held it in 4 quarters.
Weil Company's CollPlant Biotechnologies position peaked at $646K in Q2 2021.
16 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q1 2022.

Based on Weil Company's 13F filing for Q1 2022, filed 6 May 2022.